NCT02641002 - A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

July 18, 2018

Study Completion Date

July 18, 2018

Conditions

Leukemia, Myeloid, AcuteMyelodysplastic Syndromes

Interventions

DRUG

CC-90002

Monoclonal Ab to CD47

Trial Locations (6)

Memorial Sloan Kettering Cancer Center, New York

University of Chicago, Chicago

Mayo Clinic Phoenix, Phoenix

UCLA Division of Hematology Oncology, Los Angeles

Yale Cancer Center, New Haven

Dana-Farber Cancer Institute, Boston